Thiazole and thiadiazole compounds for inflammation and immune-related uses
The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein R′ 1 , X, X′, L and Y are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
1. A compound represented by formula (XI):
or a pharmaceutically acceptable salt or prodrug thereof, wherein:
L 1 is —NR—C(O)— or —C(O)—NR—;
Y′ is aryl substituted with one or more halo and/or alkyl groups;
Z is selected from the group consisting of optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteraralkyl, a haloalkyl, —C(O)NR 1 R 2 , —NR 4 C(O)R 5 , halo, —OR 4 , cyano, nitro, haloalkoxy, —C(O)R 4 , —NR 1 R 2 , —SR 4 , —C(O)OR 4 , —OC(O)R 4 , —NR 4 C(O)NR 1 R 2 , —OC(O)NR 1 R 2 , —NR 4 C(O)OR 5 , —S(O) p R 4 , and —S(O) p NR 1 R 2 ;
Z 10 is an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteraralkyl, a haloalkyl, —C(O)NR 1 R 2 , —NR 4 C(O)R 5 , halo, cyano, nitro, haloalkoxy, —C(O)R 4 , —NR 1 R 2 , —SR 4 , —C(O)OR 4 , —OC(O)R 4 , —NR 4 C(O)NR 1 R 2 , —OC(O)NR 1 R 2 , —NR 4 C(O)OR 5 , —S(O) p R 4 , or —S(O) p NR 1 R 2 ;
Z 11 is —H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteraralkyl, a haloalkyl, —C(O)NR 1 R 2 , —NR 4 C(O)R 5 , halo, —OR 4 , cyano, nitro, haloalkoxy, —C(O)R 4 , —NR 1 R 2 , —SR 4 , —C(O)OR 4 , —OC(O)R 4 , —NR 4 C(O)NR 1 R 2 , —OC(O)NR 1 R 2 , —NR 4 C(O)OR 5 , —S(O) p R 4 , or —S(O) p NR 1 R 2 ;
R, for each occurrence, is independently —H, alkyl, —C(O)—R 7 , or —C(O)OR 7 ;
R 1 and R 2 , for each occurrence are, independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl; or R 1 and R 2 taken together with the nitrogen to which they are attached is optionally substituted heterocyclyl or optionally substituted heteroaryl;
R 4 and R 5 , for each occurrence are, independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl;
R 6 , for each occurrence, is —H or alkyl;
R 7 , for each occurrence is, independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl; and
p is 0, 1, or 2.
2. The compound of claim 1 , wherein:
L 1 is —NR—C(O)—, or —C(O)—NR—;
Y′ is a substituted phenyl, wherein the substituents are each independently a lower alkyl or a halo;
Z is chloro, bromo, fluoro, cyano, trifluoromethyl, —OCH 3 , —C(O)CH 3 , 2-methyl-2H-tetrazolyl, methoxy, nitro, dimethylamino, thiazol-2-yl, oxazol-2-yl, or methyl;
Z 10 is halo or an optionally substituted lower alkyl;
Z 11 is —H, an optionally substituted lower alkyl, an optionally substituted lower alkenyl, an optionally substituted lower alkynyl, an optionally substituted cycloalkyl, —C(O)OR 4 , —C(O)R 4 , —C(O)NR 1 R 2 , —NR 1 R 2 , cyano, halo, an optionally substituted oxazolyl, an optionally substituted imidazolyl, an optionally substituted oxadiazolyl, an optionally substituted thiazolyl, an optionally substituted pyrazolyl, an optionally substituted pyridinyl, or an optionally substituted phenyl.
3. The compound of claim 2 , wherein
L 1 is —NH—C(O)— or —C(O)—NH—;
Y′ is 2,6-difluorophenyl;
Z 10 is halo or methyl; and
Z 11 is —H or methyl.
4. A compound selected from the group consisting of:
(2-(2-Chloro-5-trifluoromethyl-phenyl)-thiazole-5-carboxylic acid 2,6-difluoro-phenyl)-amide;
2-(2-Chloro-5-trifluoromethyl-phenyl)-4-methyl-thiazole-5-carboxylic acid (2,6-difluoro-phenyl)-amide;
N-(2,6-difluorophenyl)-2-(2-methyl-5-(oxazol-2-yl)phenyl)thiazole-5-carboxamide;
N-(2,6-difluorophenyl)-2-(2-methyl-5-(thiazol-2-yl)phenyl)thiazole-5-carboxamide;
N-(2,6-difluorophenyl)-2-(3-(trifluoromethyl)phenyl)thiazole-5-carboxamide;
N-(2,6-difluorophenyl)-2-(3-(oxazol-2-yl)phenyl)thiazole-5-carboxamide;
2-(2-chloro-5-(thiazol-2-yl)phenyl)-N-(2,6-difluorophenyl)thiazole-5-carboxamide; or
N-(2,6-difluorophenyl)-2-(2-methyl-5-(1,3,4-oxadiazol-2-yl)phenyl)thiazole-5-carboxamide;
or a pharmaceutically acceptable salt or prodrug thereof.
5. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of claim 4 .